S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:IARTIntegra Lifesciences Stock Price, Forecast & News

$51.25
-0.47 (-0.91 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$50.88
Now: $51.25
$51.72
50-Day Range
$45.60
MA: $47.97
$51.17
52-Week Range
$34.21
Now: $51.25
$64.24
Volume295,001 shs
Average Volume593,461 shs
Market Capitalization$4.32 billion
P/E Ratio165.32
Dividend YieldN/A
Beta1.07
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Read More
Integra Lifesciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IART
CUSIP45798520
Phone609-275-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 billion
Cash Flow$4.37 per share
Book Value$16.50 per share

Profitability

Net Income$50.20 million

Miscellaneous

Employees4,000
Market Cap$4.32 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$51.25
-0.47 (-0.91 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IART News and Ratings via Email

Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions

How has Integra Lifesciences' stock price been impacted by Coronavirus?

Integra Lifesciences' stock was trading at $46.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IART stock has increased by 11.2% and is now trading at $51.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Integra Lifesciences?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Integra Lifesciences
.

When is Integra Lifesciences' next earnings date?

Integra Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Integra Lifesciences
.

How were Integra Lifesciences' earnings last quarter?

Integra Lifesciences Holdings Corp (NASDAQ:IART) released its earnings results on Monday, August, 10th. The life sciences company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.23. The life sciences company earned $258.67 million during the quarter, compared to the consensus estimate of $252.54 million. Integra Lifesciences had a return on equity of 15.98% and a net margin of 1.76%. The business's revenue was down 32.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 earnings per share.
View Integra Lifesciences' earnings history
.

When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?

Shares of Integra Lifesciences split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.

What guidance has Integra Lifesciences issued on next quarter's earnings?

Integra Lifesciences updated its second quarter 2020 After-Hours earnings guidance on Thursday, July, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $254-256 million, compared to the consensus revenue estimate of $240.49 million.

What price target have analysts set for IART?

11 analysts have issued twelve-month price targets for Integra Lifesciences' stock. Their forecasts range from $46.00 to $68.00. On average, they anticipate Integra Lifesciences' stock price to reach $58.17 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for Integra Lifesciences
.

Has Integra Lifesciences been receiving favorable news coverage?

Media headlines about IART stock have been trending extremely negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Integra Lifesciences earned a news impact score of -4.0 on InfoTrie's scale. They also gave media stories about the life sciences company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Integra Lifesciences
.

Are investors shorting Integra Lifesciences?

Integra Lifesciences saw a increase in short interest in February. As of February 15th, there was short interest totaling 3,580,000 shares, an increase of 95.6% from the January 31st total of 1,830,000 shares. Based on an average daily volume of 479,700 shares, the short-interest ratio is currently 7.5 days. Currently, 5.1% of the company's shares are short sold.
View Integra Lifesciences' Short Interest
.

Who are some of Integra Lifesciences' key competitors?

What other stocks do shareholders of Integra Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra Lifesciences investors own include AbbVie (ABBV), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Adobe (ADBE), Advanced Micro Devices (AMD), Boeing (BA), Activision Blizzard (ATVI), Applied Materials (AMAT) and Celgene (CELG).

Who are Integra Lifesciences' key executives?

Integra Lifesciences' management team includes the following people:
  • Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
  • Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
  • Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
  • Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
  • Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)

What is Integra Lifesciences' stock symbol?

Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."

Who are Integra Lifesciences' major shareholders?

Integra Lifesciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.93%), Fisher Asset Management LLC (0.80%), Goldman Sachs Group Inc. (0.78%), FMR LLC (0.76%), GW&K Investment Management LLC (0.73%) and Tributary Capital Management LLC (0.64%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig.
View institutional ownership trends for Integra Lifesciences
.

Which major investors are selling Integra Lifesciences stock?

IART stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Jennison Associates LLC, Vanguard Group Inc., FMR LLC, Fisher Asset Management LLC, CWM LLC, State of Tennessee Treasury Department, and GW&K Investment Management LLC. Company insiders that have sold Integra Lifesciences company stock in the last year include Eric Schwartz, Glenn Coleman, John Mooradian, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Richard E Caruso, and Stuart Essig.
View insider buying and selling activity for Integra Lifesciences
.

Which major investors are buying Integra Lifesciences stock?

IART stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Nordea Investment Management AB, Strs Ohio, MUFG Securities EMEA plc, Tributary Capital Management LLC, Russell Investments Group Ltd., SG Americas Securities LLC, and Swiss National Bank. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill, and Rhonda Germany Ballintyn.
View insider buying and selling activity for Integra Lifesciences
.

How do I buy shares of Integra Lifesciences?

Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Integra Lifesciences' stock price today?

One share of IART stock can currently be purchased for approximately $51.25.

How big of a company is Integra Lifesciences?

Integra Lifesciences has a market capitalization of $4.32 billion and generates $1.52 billion in revenue each year. The life sciences company earns $50.20 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra Lifesciences employs 4,000 workers across the globe.

What is Integra Lifesciences' official website?

The official website for Integra Lifesciences is www.integralife.com.

How can I contact Integra Lifesciences?

Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.